Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
QSAM Biosciences, Inc. (QSAM)
|
Add to portfolio |
|
|
|
| Price: |
$0.22
| | Metrics |
| OS: |
3.29
|
M
| |
|
|
| Market cap: |
$720.1
|
k
| |
|
|
|
Net cash:
|
$389.7
|
k
| |
$0.12
|
per share
|
|
EV:
|
$330.4
|
k
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($7.8)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Mar-31-15 |
| Revenues | 8.3 | 0.4 | 1.8 | 0.0 | 0.1 | 0.0 | 0.6 | 0.3 |
| Revenue growth | 2086.1% | -78.7% | 5239.6% | -55.4% | 86.9% | -93.0% | | -637.6% |
| Cost of goods sold | 8.3 | 0.4 | 0.7 | 0.7 | 0.1 | 0.0 | 0.6 | 0.1 |
| Gross profit | 0.0 | 0.0 | 1.1 | -0.7 | 0.0 | 0.0 | 0.0 | 0.2 |
| Gross margin | 0.0% | 0.0% | 63.5% | -2016.5% | 15.3% | 82.1% | 2.5% | 63.8% |
| Selling, general and administrative | | | | | | 1.7 | 3.4 | |
| Research and development | 0.6 | 0.4 | | | | 0.4 | | |
| General and administrative | 2.1 | 0.6 | 0.5 | 0.9 | 1.3 | 1.1 | | 0.4 |
| EBITA | -11.0 | -1.3 | -1.1 | -1.5 | -1.6 | -2.0 | -3.3 | -0.9 |
| EBITA margin | -132.2% | -331.5% | -63.5% | -4589.2% | -2077.7% | -5008.9% | -582.7% | -339.8% |
| Amortization of intangibles | | | | | 0.0 | 0.0 | 0.0 | |
| EBIT | -11.0 | -1.3 | -1.1 | -1.5 | -1.6 | -2.0 | -3.4 | -0.9 |
| EBIT margin | -132.2% | -331.5% | -63.5% | -4589.2% | -2106.9% | -5118.3% | -590.3% | -339.8% |
| Pre-tax income | -12.0 | -5.8 | -0.6 | -0.4 | -2.7 | -1.5 | 0.0 | -0.5 |
| Income taxes | 0.0 | -1.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 16.4% | | 0.0% | 0.0% | 0.0% | | 0.0% |
| Earnings from continuing ops | -13.6 | -5.9 | -0.7 | -0.4 | -2.8 | -1.5 | | -0.5 |
| Earnings from discontinued ops | | 1.0 | 0.0 | | | | | |
| Net income | -13.6 | -4.9 | -0.7 | -0.4 | -2.8 | -1.5 | 0.0 | -0.6 |
| Net margin | -163.5% | -1291.6% | -40.3% | -1314.1% | -3678.6% | -3834.1% | 0.0% | -229.7% |
| |
| Diluted EPS | ($0.43) | ($1.06) | ($0.32) | ($0.01) | ($0.06) | ($0.05) | $0.00 | ($0.04) |
| Shares outstanding (diluted) | 31.7 | 5.5 | 2.1 | 49.9 | 46.7 | 28.4 | 16.7 | 12.6 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|